You are here:

Forthcoming Submissions:

PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
cabozantinib (Cabometyx) Ipsen Ltd Full submission 6/03/2017 2/05/2017 12/06/2017
carfilzomib (Kyprolis) Amgen Ltd Full submission 3/04/2017 Q3 2017 Q3 2017
ibrutinib (Imbruvica) Janssen-Cilag Ltd Resubmission 6/02/2017 7/03/2017 10/04/2017
liposomal irinotecan (Onivyde) Baxalta Full submission 5/12/2016 7/02/2017 13/03/2017
nivolumab (Opdivo) for Hodgkin lymphoma Bristol-Myers Squibb Pharmaceuticals Ltd Full submission 3/04/2017 Q2 2017 Q3 2017
nivolumab (Opdivo) for RCC Bristol-Myers Squibb Pharmaceuticals Ltd Resubmission 6/03/2017 2/05/2017 12/06/2017
obinutuzumab (Gazyvaro) Roche Full submission 5/12/2016 7/02/2017 13/03/2017
pembrolizumab (Keytruda) - 1st Line NSCLC MSD Full submission 3/04/2017 Q2 2017 Q3 2017
pertuzumab (Perjeta) Roche Resubmission 6/02/2017 2/05/2017 12/06/2017
trastuzumab emtansine (Kadcyla) Roche Resubmission 5/12/2016 7/03/2017 10/04/2017
venetoclax (Venclyxto) AbbVie Ltd Full submission 1/05/2017 Q3 2017 Q3 2017

Non-PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
daclizumab (Zinbryta) Biogen Idec Ltd Full submission 6/02/2017 7/03/2017 10/04/2017

Medicines with advice withheld pending product availability

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
dinutuximab (Unituxin) United Therapeutics Full submission 31/10/2015 6/01/2016 TBC

Back